• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Rapid Disk Testing for Bacterial Combinations Links to Lower Patient Mortality

by
November 18, 2026
in Health
Reading Time: 6 mins read
0
Rapid Disk Testing for Bacterial Combinations Links to Lower Patient Mortality

Rapid Disk Testing for Bacterial Combinations Links to Lower Patient Mortality

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A retrospective investigation conducted at a tertiary healthcare facility in Shanghai demonstrates that evaluating antibiotic interactions using an agar disk approximation technique was linked to reduced mortality and improved clinical response among individuals diagnosed with severe bacterial infections. Published in Frontiers in Cellular and Infection Microbiology, the study evaluated seventy-six patients infected with carbapenem-resistant Acinetobacter baumannii who underwent in vitro combination susceptibility profiling between September 2024 and June 2026. The clinical challenge posed by this pathogen is substantial, as the World Health Organization designates it a critical-priority antibiotic-resistant threat that frequently afflicts medically complex and critically ill patients. Standard therapeutic regimens often rely on drug combinations composed of sulbactam-based agents, polymyxins, and tetracyclines due to extensive antimicrobial resistance and uneven international access to newly developed targeted agents. However, conventional clinical trials evaluating empirical combination regimens have produced mixed outcomes, highlighting the urgent need for diagnostic methods that directly characterize isolate-specific drug synergies rather than relying entirely on generalized clinical assumptions.

Standard clinical microbiology routines rely on automated testing systems and disk diffusion to measure the susceptibility of an isolate to single antibiotic compounds. While informative for isolated agents, routine susceptibility workflows provide no empirical data regarding how two or three antimicrobials interact when administered simultaneously. Quantitative interaction tests such as the microdilution checkerboard assay calculate fractional inhibitory concentration indices to establish true synergy, but their high labor intensity, technical complexity, and extended turnaround times preclude widespread implementation in day-to-day diagnostic laboratories. To circumvent these operational constraints, the investigators examined a disk approximation method adapted directly from the standard Kirby-Bauer disk diffusion procedure. By positioning standard commercial antibiotic disks at fixed spatial intervals on agar plates inoculated with clinical isolates, laboratory personnel can rapidly observe structural alterations in bacterial inhibition zones. This physical proximity allows diffusing antimicrobial compounds to intersect in the culture medium, revealing synergistic or additive interactions within eighteen to twenty-four hours of incubation under routine laboratory conditions.

The study protocol established stringent eligibility criteria, including patients across all age brackets with documented clinical infection caused by carbapenem-resistant Acinetobacter baumannii who underwent disk-based combination testing. Patients who exhibited colonization without overt inflammatory signs of active infection were excluded, as were individuals receiving end-of-life palliative care or those who died within seventy-two hours following bacterial detection. The final analytic cohort comprised seventy-six patients, including forty-seven males and twenty-nine females, with an overall median age of sixty-seven years across an interquartile range spanning from nine to seventy-five years. Notably, twenty-three pediatric patients under eighteen years of age were included within this population. The distribution of primary clinical infection sites reflected severe systemic illness: bloodstream infections occurred in forty-two patients, representing 55.3 percent of the cohort, while respiratory tract infections accounted for thirty-two cases, representing 42.1 percent. Intra-abdominal infections were identified in sixteen individuals, and central nervous system infections were confirmed in seven patients across the participating medical center.

To evaluate combinations systematically, the laboratory team utilized disks containing standardized quantities of imipenem, meropenem, cefoperazone-sulbactam, levofloxacin, tigecycline, amikacin, polymyxin B, and fosfomycin. In two-drug evaluations, pairs of disks were positioned on Mueller-Hinton agar plates with a center-to-center distance of exactly twenty-four millimeters. For three-drug combinations, the disks were placed at the vertices of an equilateral triangle maintaining the same twenty-four-millimeter spacing between adjacent disks. Morphological changes in the clearance boundaries around the disks were visually classified following established criteria. Any distinct distortion or directional expansion of an inhibition zone toward an adjacent antibiotic disk was designated as a favorable interaction, encompassing both synergy and additivity. Notably, throughout the testing of all two-drug and three-drug regimens across the entire isolate panel, no antagonistic interactions were detected.

To establish the analytical credibility of the visual disk approximation technique, the investigators performed quantitative checkerboard broth microdilution validation on a purposively selected subset of nine extensively drug-resistant clinical isolates. Individual minimum inhibitory concentrations were determined in triplicate using cation-adjusted Mueller-Hinton broth. In two-drug checkerboard assays, eight-by-eight dilution matrices evaluated concentrations ranging from four times down to one-thirty-second of individual minimum inhibitory concentrations. Three-drug assays fixed the third agent at one-quarter of its individual minimum inhibitory concentration while serially diluting the remaining two compounds. When synergy, defined by a fractional inhibitory concentration index of 0.5 or less, and additivity, defined by an index greater than 0.5 up to 1.0, were grouped into a unified favorable interaction category, the visual disk approximation technique achieved complete categorical concordance with checkerboard determinations across all ninety paired assessments.

Across the complete set of seventy-six clinical isolates, the prevalence of favorable interactions varied substantially depending on the specific pharmacological agents combined. Among two-drug regimens, polymyxin B paired with cefoperazone-sulbactam, polymyxin B paired with tigecycline, and cefoperazone-sulbactam paired with tigecycline each exhibited favorable interactions in all seventy-six isolates, achieving a 100 percent synergy or additivity rate. Regimens combining fosfomycin with cefoperazone-sulbactam, polymyxin B, or tigecycline demonstrated favorable interactions in seventy-three of seventy-six isolates, yielding a 96.1 percent frequency, while polymyxin B combined with amikacin produced favorable interactions in sixty-three isolates, representing 82.9 percent. In marked contrast, combinations pairing polymyxin B with meropenem yielded favorable interactions in only forty-two isolates, or 55.3 percent. Regimens pairing cefoperazone-sulbactam with levofloxacin showed favorable interactions in thirty-nine isolates, or 51.3 percent, while imipenem combined with fosfomycin yielded thirty-seven favorable profiles, or 48.7 percent, and imipenem with tigecycline showed favorable results in thirty-four isolates, representing 44.7 percent.

Among three-drug combinations evaluated across the seventy-six bacterial isolates, the combination of cefoperazone-sulbactam, polymyxin B, and tigecycline exhibited universal synergy or additivity, achieving favorable interaction profiles in all seventy-six isolates. Combinations incorporating fosfomycin alongside cefoperazone-sulbactam and polymyxin B, cefoperazone-sulbactam and tigecycline, or polymyxin B and tigecycline each produced favorable interaction results in seventy-three isolates, representing 96.1 percent. The triplet combining cefoperazone-sulbactam, polymyxin B, and amikacin produced favorable profiles in sixty-four isolates, or 84.2 percent. Combinations incorporating levofloxacin or imipenem yielded markedly lower interaction success: cefoperazone-sulbactam, polymyxin B, and levofloxacin showed favorable patterns in forty-two isolates, representing 55.3 percent, while imipenem combined with fosfomycin and tigecycline, as well as cefoperazone-sulbactam combined with tigecycline and levofloxacin, each showed favorable interactions in forty-one isolates, representing 53.9 percent. Finally, the combination of cefoperazone-sulbactam, fosfomycin, and levofloxacin showed favorable interactions in thirty-eight isolates, representing exactly 50.0 percent.

In the clinical cohort, fifty-two patients received early favorable-interaction therapy, defined as initiating or continuing an antibiotic combination exhibiting in vitro synergy or additivity within three days of microbial detection, whereas twenty-four patients did not. Patients in the favorable-interaction cohort experienced significantly lower thirty-day all-cause mortality, with eight deaths occurring among fifty-two individuals, representing 15.4 percent, compared to fourteen deaths among twenty-four individuals who did not receive favorable therapy, representing 58.3 percent. Survival analysis was modeled from a day-three landmark corresponding to the conclusion of the early-treatment identification window. In univariable Cox regression, early favorable-interaction therapy was associated with a hazard ratio for thirty-day mortality of 0.20, with a 95 percent confidence interval from 0.08 to 0.48.

Secondary clinical outcomes similarly favored patients managed with early favorable-interaction regimens. Clinical effectiveness assessed at day fifteen following pathogen detection was achieved in forty-four of the seventy-six patients, representing 57.9 percent of the entire cohort. Among patients receiving early favorable-interaction combinations, thirty-seven of fifty-two individuals, or 71.2 percent, achieved treatment success by day fifteen, compared to seven of twenty-four patients, or 29.2 percent, in the non-favorable group. In multivariable logistic regression adjusted for baseline organ dysfunction and early appropriate therapy, early favorable-interaction regimens were associated with an adjusted odds ratio for day-fifteen effectiveness of 6.36, with a 95 percent confidence interval from 2.00 to 22.99. In contrast, early appropriate therapy, defined by single-agent in vitro susceptibility, exhibited a non-significant association following multivariable adjustment, yielding an adjusted odds ratio of 2.99 with a 95 percent confidence interval spanning from 0.79 to 12.23. Exploratory analyses regarding specific pharmacological agents indicated that fosfomycin exposure was nominally associated with increased day-fifteen treatment effectiveness, producing an adjusted odds ratio of 5.31.

The authors underscored several methodological and contextual limitations that temper direct causal interpretations of their findings. Because the study utilized a retrospective observational design conducted at a single hospital center, the documented associations are susceptible to residual confounding and confounding by clinical indication that multivariable adjustments cannot fully eliminate. Furthermore, excluding patients who succumbed within the first seventy-two hours of bacterial identification introduced potential selection bias, restricting the applicability of findings strictly to patients surviving past the day-three landmark. The modest cohort size of seventy-six patients and limited total death events restricted the statistical power of subgroup analyses, particularly regarding individual antimicrobial combinations. Additionally, the qualitative disk approximation technique relied on visual interpretation performed by a single observer without formal independent verification, and checkerboard validation was confined to a selected group of nine bacterial isolates. Consequently, the authors conclude that prospective multicenter trials and standardized testing guidelines are required before widespread clinical implementation can be formally recommended.

Subject of Research: Clinical utility of disk-based combination susceptibility testing for carbapenem-resistant Acinetobacter baumannii

Article Title: Clinical utility of rapid disk-based combination susceptibility testing in carbapenem-resistant Acinetobacter baumannii infection

Article References: Yao, H., Wang, X., Liu, J., Bu, S., Chen, J., & Jiao, Z. (2026). Clinical utility of rapid disk-based combination susceptibility testing in carbapenem-resistant Acinetobacter baumannii infection. Frontiers in Cellular and Infection Microbiology, 16, Article 1999081. https://doi.org/10.3389/fcimb.2026.1999081

Image Credits: AI Generated

DOI: 10.3389/fcimb.2026.1999081

Keywords: Acinetobacter baumannii, Carbapenem resistance, Antimicrobial susceptibility testing, Disk approximation method, Combination antibiotic therapy, Kirby-Bauer method, Checkerboard assay, Fractional inhibitory concentration index, Polymyxin B, Cefoperazone-sulbactam, Tigecycline, Fosfomycin, Hospital-acquired infections, Infectious disease epidemiology, Clinical microbiology, Survival analysis, Mortality risk

News Source: Ophelia Keating. (November 18, 2026). Rapid Disk Testing for Bacterial Combinations Links to Lower Patient Mortality. Scienmag.

Tags: Acinetobacter baumanniiantimicrobial susceptibility testingCarbapenem resistancecefoperazone-sulbactamcheckerboard assayclinical microbiologyCombination antibiotic therapyDisk approximation methodfosfomycinFractional Inhibitory Concentration Indexhospital-acquired infectionsinfectious disease epidemiologyKirby-Bauer methodmortality riskpolymyxin Bsurvival analysistigecycline
Share12Tweet7Share2ShareShareShare1

Related Posts

Targeted Biomarker Phenotyping Guides Recurrent Preschool Wheezing Care in Expert Consensus

Targeted Biomarker Phenotyping Guides Recurrent Preschool Wheezing Care in Expert Consensus

November 18, 2026
Digital Health Access Linked to Calorie Information Use in Prepared Meals

Digital Health Access Linked to Calorie Information Use in Prepared Meals

November 18, 2026

Neuromuscular Training Reduces Athletic Lower-Limb Injury Risk Despite Evidence Uncertainties

November 18, 2026

Enhanced Recovery After Surgery May Shorten Stays in Ureteroscopic Lithotripsy

November 18, 2026

POPULAR NEWS

  • T Cell Depletion Protects Dopaminergic Neurons After Head Injury in Mice

    T Cell Depletion Protects Dopaminergic Neurons After Head Injury in Mice

    29 shares
    Share 12 Tweet 7
  • Ear-Based Nerve Stimulation Shows Preliminary Cognitive Benefits in Spinal Cord Pilot

    29 shares
    Share 12 Tweet 7
  • Visuospatial Memory Game Reveals Interpretable Behavioral Profiles in Children With ADHD

    29 shares
    Share 12 Tweet 7
  • Core-Shell Zinc Oxide and Bismuth Sulfide Photoanodes Boost Solar Hydrogen Production

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Hybrid Graph-Based Detectors Boost Rectangle Landmark Accuracy for Mobile Robot Localization

Asphalt Paving Block Thickness and Rubber Grain Size Determine Structural Load Capacity

Targeted Biomarker Phenotyping Guides Recurrent Preschool Wheezing Care in Expert Consensus

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.